Investor Overview

About Selecta

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology... View more »

Upcoming Events

There are currently no events to display.

Copyright Nasdaq. Minimum 15 minutes delayed.

Stock Quote

: (Common Stock)

Copyright Nasdaq. Minimum 15 minutes delayed.

IR Contact
Sarah McCabe
Stern Investor Relations, Inc.
Phone: 212-362-1200
E-mail: sarah@sternir.com